Find molecules with large global trade but few ANDA filings. The white-space radar for first-mover or fast-follower generic strategy.
Vildagliptin carries $9.5B of cumulative global trade across 22 markets with zero active US ANDA filings. Bilastine sits at $9.7B across 8 markets, also zero ANDA. Cholecalciferol is a $17.7B vitamin-D market with two filings. Lumefantrine ($72M trade, zero filings) is the antimalarial white-space. Each is a candidate for a first-mover or fast-follower generic strategy, with the trade size as the demand signal and the ANDA gap as the entry-cost mitigator.
| # | Molecule | Cumulative trade | Markets | Active ANDAs | Posture |
|---|---|---|---|---|---|
| 1 | Vildagliptin | DPP-4 · diabetes | 22 active markets | $9.5B · 0 ANDA | NAI |
| 2 | Bilastine | Antihistamine | 8 active markets | $9.7B · 0 ANDA | NAI |
| 3 | Cholecalciferol | Vitamin D · nutrition | 27 active markets | $17.7B · 2 ANDA | NAI |
| 4 | Lumefantrine | Antimalarial | 25 active markets | $72M · 0 ANDA | NAI |
| 5 | Mebendazole | Antiparasitic | 18 active markets | $3.2B · 1 ANDA | NAI |
All molecules above a trade threshold, or a therapy area or class. Default surface is molecules with cumulative global trade over $5M and fewer than 5 active ANDA filings.
Cumulative trade size, active-market count, and active ANDA count joined to FTO complexity (active patent count). Each candidate carries the full signal.
Citation-anchored brief with the top targets ranked by trade size, the FTO posture per candidate, and a recommended portfolio-priority list.
Vildagliptin and bilastine clear $9B of global trade with zero US ANDAs. The trade tells the demand story; the ANDA gap is the entry opportunity.
Active in 22 markets without an ANDA implies the molecule has commercial traction outside the US. A first-mover ANDA captures both the US share and the global supply chain that the candidate molecule already runs.
Active patent count surfaces alongside ANDA count. A zero-ANDA molecule with 11 active patents has different economics than a zero-ANDA molecule with 1 active patent.
Trade growth combined with ANDA gap is the white-space-growth signal. The AI agent ranks candidates by both dimensions and recommends the top three for portfolio approval.
A real chat thread in PharmaDB. Type a question, the AI agent runs the tools, the answer lands as a saveable note.
pharmagraph_query Twelve molecules with cumulative trade over $10M and fewer than 5 active US ANDAs · count is active markets · the demand-breadth signal.
The limited-competition radar is the white-space targeting view for portfolio teams. PharmaDB joins cumulative global trade to active ANDA filings and surfaces the molecules where demand exceeds filing density. The view is molecule_country_flow; the join is to filings for the ANDA-count gate.
Vildagliptin is approved outside the US through EU and ROW pathways but has not had a US NDA-to-ANDA path open at scale. The trade carries the global demand signal; the US ANDA gap is structural. The brief surfaces both.
Cumulative global trade over $5M combined with fewer than 5 active US ANDA filings. Both thresholds tunable. The default surfaces the white-space candidates ranked by trade size.
Sum of declared global export USD across all destinations and all observable years for the molecule. The view is molecule_country_flow aggregated to the molecule level.
Vitamin D's global trade scale is huge ($17.7B cumulative) but the US ANDA register treats it as a nutritional supplement in most pack sizes, which makes the formal ANDA count thin. The brief flags it as a borderline case and surfaces the dietary-supplement overlap.
Limited-competition targets are the present-tense view: which molecules are open now. The LOE calendar is the forward-looking version: which molecules open up in the next 24 months. Run together for portfolio sequencing across the present-tense and forward windows.
Trade aggregates refresh weekly. ANDA filings refresh weekly. The white-space scan recomputes on every refresh. The catalog row carries the last-computed timestamp surfaced on every result page.
Bring the molecule, the lane, or the supplier you're sourcing this week. The AI agent runs it on PharmaDB in 30 minutes. You keep the brief.